

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

**PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
AND RULES OF PROCEDURES;
PROPOSED AMENDMENTS TO THE TERMS OF REFERENCE FOR
INDEPENDENT NON-EXECUTIVE DIRECTORS;
RESIGNATION OF DIRECTOR;
ELECTION OF DIRECTORS OF THIRD SESSION OF
BOARD OF DIRECTORS;
AND
ELECTION OF SUPERVISORS OF THIRD SESSION OF BOARD OF
SUPERVISORS**

Reference is made to the announcement of CanSino Biologics Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) dated May 15, 2023 in relation to the postponement of re-election of the board (the “**Board of Directors**”) of directors (the “**Directors**”) and the board (the “**Board of Supervisors**”) of supervisors (the “**Supervisors**”) of the Company.

The Company held the fifteenth extraordinary meeting of the second session of the Board of Directors on January 19, 2024, to consider and approve, among other things, (i) the proposed amendments to the articles of association of the Company (the “**Articles of Association**”) and the relevant rules of procedures of the Company; (ii) the proposed amendments to the Terms of Reference for Independent Non-Executive Directors (the “**Terms of Reference**”); (iii) the proposed election of Directors of the third session of the Board of Directors; and (iv) the proposed election of Supervisors of the third session of the Board of Supervisors.

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND RULES OF PROCEDURES

In view of the fact that the China Securities Regulatory Commission and Shanghai Stock Exchange published relevant regulatory rules recently, and the Board of Directors intends to adjust the number of members of the Board of Directors for election at expiration of office terms, in order to continually comply with regulatory requirements, according to the Company Law of the PRC, the Rules Governing the Listing of Stocks on the Science and Technology Innovation Board of Shanghai Stock Exchange (Revised in August 2023), the Management Measures for Independent Directors of the Listed Company, the Guidelines for the Self-Regulation of Companies Listed on the Science and Technology Innovation Board of Shanghai Stock Exchange No. 1 – Standardized Operations (Revised in December 2023), the Supervisory Guideline for Listed Companies No. 3 – Cash Dividends for Listed Companies (Revised in 2023) and other relevant laws, administrative regulations and normative documents, together with the Company's business development needs, the Company proposed to revise the Articles of Association, the Rules of Procedure of Board of Directors and the Rules of Procedure of Board of Supervisors (together, the “**Rules of Procedures**”) accordingly.

The proposed amendments to the Articles of Association and the Rules of Procedures are subject to the approval of the shareholders of the Company (the “**Shareholders**”) at the extraordinary general meeting of the Company (the “**EGM**”) by way of a special resolution.

PROPOSED AMENDMENTS TO THE TERMS OF REFERENCE FOR INDEPENDENT NON-EXECUTIVE DIRECTORS

In view of the fact that the China Securities Regulatory Commission and Shanghai Stock Exchange published relevant regulatory rules recently, in order to further improve the governance structure of the Company, promote regulatory operations of the Company and protect the interests of the Company and all Shareholders, according to the Company Law of the PRC, the Rules Governing the Listing of Stocks on the Science and Technology Innovation Board of Shanghai Stock Exchange (Revised in August 2023), the Management Measures for Independent Directors of the Listed Company, the Guidelines for the Self-Regulation of Companies Listed on the Science and Technology Innovation Board of Shanghai Stock Exchange No. 1 – Standardized Operations (Revised in December 2023) and other relevant laws, administrative regulations and normative documents, the Company proposed to revise the Terms of Reference accordingly.

The proposed amendments to the Terms of Reference are subject to the approval of the Shareholders at the EGM by way of an ordinary resolution.

RESIGNATION OF DIRECTOR

The Board of Directors hereby announces that Mr. Zhi XIAO (“**Mr. XIAO**”) has tendered his resignation as a non-executive Director due to his personal work arrangements, with effect on the date of election of the third session of the Board of Directors at the EGM. During this period, Mr. XIAO will continue to perform his duties as a non-executive Director in accordance with the provisions of laws, regulations and the Articles of Association.

Mr. XIAO has confirmed that he has no disagreement with the Company and the Board of Directors, and there are no other matters relating to his resignation that need to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and the Shareholders.

The Board of Directors would like to take this opportunity to thank Mr. XIAO for his valuable contributions to the Group during his tenure of office.

ELECTION OF DIRECTORS OF THIRD SESSION OF BOARD OF DIRECTORS

As the term of office of the second session of the Board of Directors has expired, the Board of Directors has approved the following matters and proposed appointment of each candidate for the third session of the Board of Directors as listed below, subject to the approval of Shareholders at the EGM to be held in due course:

Executive Directors	Dr. Xuefeng YU, Dr. Shou Bai CHAO, Ms. Jing WANG (王靖)
Non-Executive Director	Ms. Nisa Bernice Wing-Yu LEUNG (梁穎宇)
Independent Non-executive Directors	Mr. Shuifa GUI (桂水發), Mr. Jianzhong LIU (劉建忠), Mr. Yiu Leung Andy CHEUNG (張耀樑)

Save for Mr. Yiu Leung Andy CHEUNG (張耀樑), all of the director candidates are existing Directors. All of the director candidates meet the qualification requirements to serve as directors as stipulated in relevant laws, regulations and the Articles of Association. They will officially assume office when the resolution on election of the third session of the Board of Directors is considered and approved at the EGM, at which the third session of the Board of Directors will be established, with a term of office expiring when the term of the third session of the Board of Directors (3 years) ends.

The biographies of the director candidates are set out in Appendix I to this announcement.

As of the date of this announcement and as far as the Board of Directors is aware, save as disclosed in Appendix I to this announcement, each of the director candidates has confirmed that (i) they do not hold directorship in other listed companies for the past three years, have no any other major appointment and professional qualifications nor any position in the Group for the last three years; (ii) they do not have any relationship with any Directors, Supervisors, senior management or substantial or controlling Shareholders of the Company; and (iii) they do not have any interest in the shares of the Company or its associated corporation within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed in Appendix I to this announcement, there is no other information required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange (the “**Hong Kong Listing Rules**”), nor are there other matters regarding the appointment of the director candidates as executive Directors, non-executive Directors or independent non-executive Directors which need to be brought to the attention of the Shareholders. The director candidates have not been subject to any penalty or punishment imposed by the China Securities Regulatory Commission or any other relevant authorities or stock exchanges.

As of the date of this announcement, the Company has not entered into any service contract with the director candidates in relation to the appointment of Directors for the third session of the Board of Directors. Upon approval of the appointment of the director candidates at the EGM, the Company will enter into service contracts with the Directors. Each of the Directors shall be eligible for re-election upon expiry of their terms of office pursuant to the Articles of Association.

The nomination committee of the Company (the “**Nomination Committee**”) assists the Board of Directors in the selection and nomination process for the proposed independent non-executive Directors. The Nomination Committee followed the board diversity policies of the Company and evaluated the director candidates based on criteria including but not limited to their character and integrity, professional qualifications, skills, knowledge, experience and willingness and ability to devote adequate time to discharge duties as members of the Board of Directors. The Nomination Committee considers that the proposed independent non-executive Directors have a balanced mix of knowledge, skills and experience in areas including finance, accounting, business administration and healthcare, and will continue to bring valuable business experience, knowledge and professionalism to the Board of Directors for its efficient and effective functioning. The Nomination Committee has also assessed and reviewed the written confirmation of independence of each of Mr. Shuifa GUI (桂水發), Mr. Jianzhong LIU (劉建忠) and Mr. Yiu Leung Andy CHEUNG (張耀樑) and is satisfied that they are independent in accordance with Rule 3.13 of the Hong Kong Listing Rules. Accordingly, the Nomination Committee has recommended to the Board of Directors on election of all the proposed independent non-executive Directors.

ELECTION OF SUPERVISORS OF THIRD SESSION OF BOARD OF SUPERVISORS

As the term of office of the second session of the Board of Supervisors has expired, the Board of Supervisors has approved the following matters and proposed appointment of each candidate as non-employee representative Supervisor for the third session of the Board of Supervisors as listed below, subject to the approval of Shareholders at the EGM:

Non-employee representative Supervisors Mr. Zhi XIAO (肖治), Dr. Zhongqi SHAO (邵忠琦)

Dr. Zhongqi SHAO (邵忠琦) is an existing Supervisor. All of the supervisor candidates meet the qualification requirements to serve as non-employee representative Supervisors as stipulated in relevant laws, regulations and the Articles of Association. They will officially assume office when the resolution on election of the third session of the Board of Supervisors is considered and approved at the EGM, at which the third session of the Board of Supervisors will be established, with a term of office expiring when the term of the third session of the Board of Supervisors (3 years) ends. The employee representative Supervisors will be elected by the employee representative meeting of the Company.

The biographies of the supervisor candidates are set out in Appendix II to this announcement.

As of the date of this announcement and as far as the Board of Directors is aware, save as disclosed in Appendix II to this announcement, each of the supervisor candidates have confirmed that (i) they do not hold directorship in other listed companies for the past three years, have no any other major appointment and professional qualifications nor any position in the Group; (ii) they do not have any relationship with any Directors, Supervisors, senior management or substantial or controlling Shareholders of the Company or its associated corporation; and (iii) they do not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed in Appendix II to this announcement, there is no other information required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Hong Kong Listing Rules, nor are there other matters regarding the appointment of the supervisor candidates as Supervisors which need to be brought to the attention of the Shareholders. The supervisor candidates have not been subject to any penalty or punishment imposed by the China Securities Regulatory Commission or any other relevant authorities or stock exchanges.

As of the date of this announcement, the Company has not entered into any service contract with the supervisor candidates in relation to the appointment of Supervisors for the third session of the Board of Supervisors. Upon approval of the appointment of the supervisor candidates at the EGM and establishment of the third session of the Board of Supervisors, the Company will enter into service contracts with the Supervisors. Each of the Supervisors shall be eligible for re-election upon expiry of their terms of office pursuant to the Articles of Association.

GENERAL

A circular of the Company containing, among other things, detailed information of the above-mentioned (i) the proposed amendments to the Articles of Association and the Rules of Procedures, (ii) the proposed amendments to the Terms of Reference, and (iii) the proposed election of third session of the Board of Directors and the Board of Supervisors, will be despatched to the Shareholders in due course.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, January 19, 2024

As of the date of this announcement, the Board of Directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive Directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.

APPENDIX I

Biographical Details of Director Candidates

Xuefeng YU, aged 60, is a co-founder of our Company. Dr. Yu was appointed as an executive Director in 2009. He has also served as chief executive officer since 2009. He is also currently a member of Nomination Committee. He is primarily responsible for overseeing strategic development, overall operations and management and major decision-making of our Group. Dr. Yu obtained a bachelor's degree in Biology and a master's degree in Microbiology from Nankai University in July 1985 and June 1988, respectively. He obtained a Ph.D in Microbiology from McGill University in June 1998. He has more than 30 years' experience in biotech R&D. Prior to founding our Company, Dr. Yu worked for Sanofi Pasteur Limited., one of the world's leading vaccine companies since 1998 as a product development scientist, director of the Canadian division of bacterial vaccine development and global director of bacterial vaccine development. Before joining Sanofi Pasteur Limited., Dr. Yu worked for IBEX Biotechnologies Inc. (a company listed on Toronto Stock Exchange Venture Exchange, ticker symbol: IBT) as a scientist responsible for development of therapeutic enzymes from 1996 to 1998. Dr. Yu has extensive experience in the development of biological products, enterprise operation and management. He led the introduction of a new recombinant TB vaccine candidate from McMaster University in Canada, which has been supported by Aeras Global TB Vaccine Foundation and the Ministry of Science and Technology of China. He also led the introduction of adenovirus vector cell lines and related production technologies from the National Research Council of Canada, which laid the foundation for the development of vaccines such as Ad5-EBOV and Ad5-nCoV. For more than 10 years, Dr. Yu has attracted senior talents from the vaccine industry in China and abroad to assemble a team of cutting-edge experts for the Company. Under his leadership, the Company has developed a rich pipeline for 17 vaccines covering more than 10 infectious diseases. As the Chairman and CEO of the Company, Dr. Yu has strategically positioned the Company to become a China and Hong Kong dually listed company from the perspective of corporate development, raising significant amount of proceeds to support Company's development. He is highly respected by investment community. As of the date of this announcement, Dr. Yu was interested in 34,598,400 H Shares and 42,579,625 A Shares.

Shou Bai CHAO, aged 61, was appointed as an executive Director in 2018 and chief operating officer in the same year. He is also currently a member of Remuneration and Assessment Committee. He is primarily responsible for the management of daily operations and strategy development of our Group, including production management, quality control, supply chain management and information system construction. In July 1982, Dr. Chao received a bachelor's degree in inorganic chemical engineering from Jiangxi Institute of Technology (currently known as Nanchang University), a master's degree in chemical metallurgy from the Chinese Academy of Sciences in July 1985, and a Ph.D in biochemical engineering from the University of Waterloo, Canada in October 1992. With over 30 years' experience in the biotechnology industry, prior to joining the Company, he worked for Sanofi Pasteur, Pfizer, AstraZeneca and other world-renowned multinational pharmaceutical companies, serving as technical and senior management positions. He has extensive experience in R&D, production, supply chain, quality assurance and commercialization in the field of vaccines and biopharmaceuticals, especially in large-scale industrial production management and global commercial operations. Dr. Chao has a deep understanding of global GMP regulations. He established a global biopharmaceutical large-scale commercial production system and facilities for AstraZeneca during the time when he served as senior vice president of global biopharmaceuticals of AstraZeneca, which successfully obtained approval from the U.S. Food and Drug Administration and the European Medicines Agency. The system and facilities were named the best production facilities by International Society for Pharmaceutical Engineering (ISPE) in 2011. With Dr. Chao's leadership, our Company has built a strong operation team. Since joining the Company, Dr. Chao has made outstanding contributions to the Company's IPO and financing, development and production of the COVID-19 vaccine and meningococcal combined vaccines, and the establishment of a talent system. In the COVID-19 vaccine project, Dr. Chao led the commercial scale manufacturing, quality system management, talent system establishment and team expansion, to ensure that the company launched a safe and effective, high quality COVID-19 vaccine efficiently. In addition, Dr. Chao also led in the large scale production of COVID-19 vaccines to ensure its supply. As of the date of this announcement, Dr. Chao was deemed to be interested in 11,924,700 H Shares and 4,409,500 A Shares held by his spouse, Dr. Helen Huihua MAO.

Jing WANG (王靖), aged 42, was appointed as an executive Director in 2021. She has served as chief commercial officer and deputy general manager of the Group since 2021, responsible for the management of overall commercial operation of the Group. Ms. Wang has been serving as a director of CanSino SPH, a subsidiary of the Company, since 2021. Ms. Wang has served as chief financial officer of the Company from 2020 to 2021, and the secretary of the Board from 2017 to 2021. Ms. Wang holds a bachelor degree in economics, a master degree in engineering of Peking University and Global EMBA of China Europe International Business School. Ms. Wang has nearly 20 years of experience in the pharmaceutical industry. She is good at capital market operation, strategic financing, financial management, domestic and foreign marketing, corporate management, etc. After joining the Company in 2012, Ms. Wang has led the establishment of our financing, financial operations, human resource and administration systems as well as completing the pre-IPO fundraising of approximately RMB743 million. Ms. Wang successfully led the Company's IPO on the Main Board of the Hong Kong Stock Exchange in 2019 and on the Sci-tech Innovation Board of the Shanghai Stock Exchange in 2020, making the Company the first "A+H" dual listing vaccine company. In order to further promote the commercialization of the Company's products, Ms. Wang is leading the development and expansion of the Company's commercial operation center.

Nisa Bernice Wing-Yu LEUNG (梁穎宇), aged 53, was appointed as a non-executive Director in 2015. She is also currently a member of Nomination Committee. Ms. Leung is primarily responsible for participating in formulating the Company's corporate and business strategies. Ms. Leung joined Qiming Venture Partners, a venture capital firm in China, in 2007, and currently serves as a managing partner where she leads its health care investments. Ms. Leung also co-founded Biomedic Holdings Limited, which has operations and investments in medical devices, pharmaceuticals and health care services in China, in 2004. Ms. Leung was a venture partner at PacRim Venture Partners from 2001 to 2003. Ms. Leung served as a director at Gan & Lee Pharmaceutical Holdings Ltd. (甘李藥業股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 603087), from 2010 to 2021; a non-executive director of New Horizon Health Limited (諾輝健康), a company listed on the Hong Kong Stock Exchange (stock code: 6606) from 2018 to 2022; and as vice-chairwoman to the board of directors from 2013 to 2023 and a non-executive director from 2019 to 2023 of Venus Medtech (Hangzhou) Inc. (杭州啟明醫療器械股份有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 2500). Ms. Leung served as a director since 2014 and an independent director since 2020 of Zai Lab Limited (再鼎醫藥有限公司), a company listed on Nasdaq Stock Market (ticker symbol: ZLAB) and the Hong Kong Stock Exchange (stock code: 9688); and an independent non-executive director since 2021 of Hong Kong Exchanges and Clearing Limited, a company listed on the Hong Kong Stock Exchange (stock code: 388). Ms. Leung was appointed as a Justice of the Peace in July 2016 by the Government of Hong Kong. Ms. Leung received a bachelor's degree in management from Cornell University in the United States in May 1992 and a master's degree in business administration from Stanford University in the United States in June 2001. As of the date of this announcement, Ms. Leung was interested in 143,471 H Shares.

Shuifa GUI (桂水發), aged 58, was appointed as an independent non-executive Director in 2019. He is also currently the chairman of Remuneration and Assessment Committee and a member of Nomination Committee and Audit Committee. Mr. Gui is primarily responsible for supervising and providing independent judgement to the Board. Mr. Gui has been serving as director and chief financial officer at Ucloud Technology Co., Ltd. (優刻得科技股份有限公司) (a company listed on Shanghai Stock Exchange, stock code: 688158) since 2018, and as secretary of the board at Ucloud Technology Co., Ltd. from 2018 to 2023. Mr. Gui has been director of several companies, including executive director of Shanghai Shiniu Asset Management Co., Ltd. (上海師牛資產管理有限公司) since 2013, director of Shanghai Tunnel Engineering Co., Ltd. (上海隧道工程股份有限公司) (a company listed on Shanghai Stock Exchange, stock code: 600820) since 2018, independent non-executive director of Shanghai Mechanical & Electrical Industry Co., Ltd. (上海機電股份有限公司) (a company listed on Shanghai Stock exchange, stock code: 600835) since 2018, and independent non-executive director of Linkage Software Co., Ltd. (蘇州工業園區凌志軟件股份有限公司) (a company listed on Shanghai Stock Exchange, stock code: 688588) since 2019. Mr. Gui worked at Shanghai University of Finance and Economics (上海財經大學) and served as a teaching associate from 1989 to 1993. He served as business manager of Listing Department at Shanghai Stock Exchange from 1994 to 1997 and served as deputy director and director of Marketing Development Department from 1998 to 2001. From 2001 to 2011, he served as deputy general manager, chief financial officer and secretary of the board at Orient Securities Co., Ltd. (東方證券股份有限公司) (a company listed on Hong Kong Stock Exchange, stock code: 03958 and Shanghai Stock Exchange, stock code: 600958). He served as chairman of the board at China Universal Asset Management Co., Ltd. (匯添富基金管理有限公司) from 2004 to 2012. From 2012 to 2017, he served as president at Landgent Group Co., Ltd. (樂成集團有限公司). From 2017 to 2018, he served as deputy general manager at E-Capital Transfer Co., Ltd. (證通股份有限公司). Mr. Gui obtained his bachelor's degree in accounting from Shanghai University of Finance and Economics in June 1989. He received his master's degree in business management from the University of Hong Kong in September 2004. He has been a member of the Chinese Institute of Certified Public Accountants (中國註冊會計師協會) since April 1998.

Jianzhong LIU (劉建忠), aged 59, was appointed as an independent non-executive Director in 2019. He is also currently the chairman of Nomination Committee and a member of Remuneration and Assessment Committee. Mr. Liu is primarily responsible for supervising and providing independent judgement to the Board. Mr. Liu has been serving as vice president at Yingu Holdings Group Co., Ltd. (銀谷控股集團有限公司) since 2012, as dean of Zhongyi (Beijing) Vaccine and Health Institute (中義(北京)健康研究院) since 2016, as general manager and executive director at Mianzhu Yingu Rose Trading Co., Ltd. (綿竹銀谷玫瑰商貿有限公司) since 2015. Mr. Liu served as chief of Disease Control Division of the General Administration of Quality Supervision, Inspection and Quarantine (國家質量監督檢驗檢疫總局) from 1989 to 2003. From 2003 to 2011, he served as director of Scientific Affairs Department at Sanofi Pasteur, the vaccines division of the pharmaceutical company Sanofi S.A. Mr. Liu obtained his bachelor's degree in medicine from Peking University Health Science Center (北京大學醫學部) in June 1989. He received his master's degree in health sciences from Curtin University in Australia in March 1998. As of the date of this announcement, Mr. Liu was interested in 1,000 H Shares.

Yiu Leung Andy CHEUNG (張耀樑), aged 64, was appointed as an Independent Non-executive Director with effect from the date of the approval of Shareholders at the EGM. Mr. Cheung is primarily responsible for supervising and providing independent judgement to the Board.

Mr. Cheung has over 30 years of professional accounting and auditing experience. He has been serving as an independent non-executive director and chairman of the audit committee of Hua Medicine (華領醫藥), a company listed on Hong Kong Stock Exchange (stock code: 2552), and an independent non-executive director and chairman of the audit committee of JW (Cayman) Therapeutics Co. Ltd (藥明巨諾(開曼)有限公司), a company listed on Hong Kong Stock Exchange (stock code: 2126). He has also been serving as an independent director and the chairman of audit committee of Adagene Inc. (天演藥業), a company listed on Nasdaq Stock Market (stock code: ADAG).

From July 2018 to June 2020, Mr. Cheung was the deputy area managing partner of Ernst & Young (“EY”) in Asia Pacific, overseeing its business operations, finance, information technology and risk management functions. He was a member of EY Asia Pacific's Area Operating Committee, EY's Global Accounts Committee and EY's Global Markets and Investment Committee during that period. From July 2013 to June 2018, Mr. Cheung was EY's assurance leader in Greater China, managing its audit, financial accounting advisory, forensic and climate changes and sustainability services in Greater China. He was a member of EY Greater China's Leadership Team during that period. Mr. Cheung's other prior responsibilities with EY include the chief operating officer of EY Hua Ming LLP, an assurance partner of EY China and EY's area chief financial officer in Asia. Prior to joining EY in 2006, Mr. Cheung was an assurance partner in PricewaterhouseCoopers China and Arthur Andersen in China and Hong Kong successively.

Mr. Cheung received his bachelor's degree in accounting and finance from the University of Lancaster in the United Kingdom and obtained a master's degree in accounting and finance from London School of Economics in the United Kingdom. Mr. Cheung has been a member of Hong Kong Institute of Certified Public Accountants since October 1986 and served as a member of its disciplinary panel from January 2015 to December 2020.

APPENDIX II

Biographical Details of Supervisor Candidates

Zhi XIAO (肖治), aged 45, was appointed as a non-executive Director since 2019. Mr. Xiao has been the managing director of SDIC Fund Management Co., Ltd. (國投創新投資管理有限公司) since 2016. Mr. Xiao has been serving as a director of Zhejiang Novus Pharmaceuticals Co., Ltd. (浙江創新生物有限公司), a director of Beijing Surgerii Robotics Co., Ltd (北京術銳機器人股份有限公司), a director of Tinavi Medical Technologies Co., Ltd. (北京天智航醫療科技股份有限公司) (a company listed on the STAR Market of Shanghai Stock Exchange, stock code: 688277) and a director of Tofflon Science And Technology Group Co., Ltd. (東富龍科技集團股份有限公司) (a company listed on the ChiNext Market of Shenzhen Stock Exchange, stock code: 300171). Mr. Xiao served as an independent non-executive director of Guangdong Great River Smarter Logistics Co., Ltd. (廣東宏川智慧物流股份有限公司) (a company listed on the Shenzhen Stock Exchange, stock code: 002930) from 2016 to 2021. Mr. Xiao received his bachelor's degree in veterinary medicine from China Agricultural University, received his master of business administration degree from Tsinghua University and master degree from Tsinghua University School of Medicine.

Zhongqi SHAO (邵忠琦), aged 61, served as a vice president of the Company since 2011 and was appointed as a Supervisor in 2021. Dr. Shao is primarily responsible for assisting the chief scientific officer in managing R&D of the Company. Dr. Shao served as a senior research scientist in IBEX Technologies Inc. (a company listed on Toronto Stock Exchange Venture Exchange, ticker symbol: IBT) from 1995 to 2001 and from 2002 to 2007. From 2001 to 2002, he served as a senior research scientist in BioMarin Pharmaceutical Inc. From 2007 to 2011, he served as a senior research scientist in Sanofi Pasteur Limited. Dr. Shao obtained a Ph.D. in microbiology from Concordia University in August 1993. As of the Date of this announcement, Dr. Shao was interested in 675,000 H Shares.